Recombinant IL-2/diphtheria toxin fusion protein (rIL-2/DTx), a drug that is FDA-approved for the treatment of cutaneous T cell lymphoma, has been reported to deplete regulatory CD4+ T cells. This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.